Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207150 | 0.81 | TGFBR1 (0.47) | HCRTR1TGFBR1IRAK4 | |
| SCHEMBL16321221 | 0.79 | ALDH1A1 (0.44) | HCRTR1CSNK1DCSNK1ETGFBR1IDH1 | |
| SCHEMBL20028677 | 0.79 | TGFBR1 (0.47) | CSNK1DCSNK1ETGFBR1GRIN2BTAS2R14 | |
| SCHEMBL28648256 | 0.77 | TGFBR1 (0.40) | HCRTR1CSNK1DCSNK1ETGFBR1GRIN2B | |
| SCHEMBL19207143 | 0.77 | TGFBR1 (0.43) | HCRTR1CSNK1DCSNK1ETGFBR1IRAK4 | |
| SCHEMBL16003311 | 0.74 | PDE10A (0.53) | TGFBR1GRIN2BPDE10AIDH1IDH2 | |
| SCHEMBL19207096 | 0.73 | BRD4 (0.47) | HCRTR1 | |
| SCHEMBL8895248 | 0.72 | CA12 (0.46) | TGFBR1IDH1IDH2TAS2R14P2RX7 | |
| SCHEMBL8889787 | 0.71 | CA12 (0.51) | HCRTR1TGFBR1 | |
| SCHEMBL2817067 | 0.70 | HCRTR1 (0.42) | HCRTR1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2022-09-06 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109219606-B | Halogen substituted piperidines as orexin receptor modulators | 阿斯利康(瑞典)有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3414241-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885CSNK1D 1213/4885CSNK1E 2364/4885 |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885CSNK1D 1213/4885CSNK1E 2364/4885 |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885CSNK1D 1213/4885CSNK1E 2364/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885CSNK1D 1213/4885CSNK1E 2364/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885CSNK1D 1213/4885CSNK1E 2364/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885CSNK1D 1213/4885CSNK1E 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.